Klin Onkol 1999; 12(3): 101-104.
Summary: Background: There are several possibilities fore induction therapy iof patients with acute myeloid leukemia (AML.) Since 1997, we have used a modern ICE protocol in our department. In this article, we describe our results. Design and subjects: We treated 20 patients with induction therapy ICE: idarubicin 10mg/m2/day, days 1-3; cytosinarabinosid 100mg/m2 /day in continuous infusion, days 1-7; etoposide 100mg/m2/day, days 1-5. Particular concern was devoted to toxicity of administered therapy. Results: Complete remission was achieved in 70% of treated patients, 10% did not achieved remission, and 20% of patients died during the induction therapy. The induction therapy was accompanied by many infectious as well as non-infectious complications. These are common duriong the induction treatment. The therapy is very expensive, Conclusion: AML is serious, rapidly progressing and life-threatening disease, which needs urgent treatment at a specialized department.
